ARTICLE | Clinical News

Pertuzumab: Phase III data

July 18, 2011 7:00 AM UTC

The double-blind, international Phase III CLEOPATRA trial in 808 previously untreated HER2-positive breast cancer patients showed that IV pertuzumab every 3 weeks plus Herceptin trastuzumab and docetaxel met the primary endpoint of PFS vs. Herceptin plus docetaxel alone. No new safety signals were observed. Roche's Genentech Inc. unit said it plans to submit the results for global regulatory approval this year, but did not disclose details. ...